Pulmonary Embolism - Pipeline Review, H2 2020
Pulmonary Embolism - Pipeline Review, H2 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2020, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.
Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 2, 1 and 1 respectively.
Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2020, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.
Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 2, 1 and 1 respectively.
Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Pulmonary Embolism - Overview
Pulmonary Embolism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pulmonary Embolism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pulmonary Embolism - Companies Involved in Therapeutics Development
Acticor Biotech SAS
China Resources Emde Biological Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
Indiana Lysis Technologies LLC
Les Laboratoires Servier SAS
Tasly Pharmaceutical Group Co Ltd
Tianjin Pharmaceuticals Group Co Ltd
Valeo Pharma Inc
Verseon Corp
Pulmonary Embolism - Drug Profiles
ACT-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Pulmonary Embolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Redesca - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pulmonary Embolism - Dormant Projects
Pulmonary Embolism - Discontinued Products
Pulmonary Embolism - Product Development Milestones
Featured News & Press Releases
Nov 14, 2019: Valeo Pharma announces filing of a New Drug Submission for Low Molecular Weight Heparin in Canada
Oct 25, 2017: IU-based drug-discovery startup aims to use nanotechnology to digest blood clots in lungs
Oct 11, 2017: IU-based drug-discovery startup wins $10,000 in BioCrossroads New Venture Competition
Feb 23, 2017: Daiichi Sankyo Europe Receives CHMP Positive Opinion for Roteas (edoxaban)
Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
Nov 09, 2016: Once-Daily Anticoagulant LIXIANA (edoxaban) Approved in Canada for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrent Deep-Vein Thrombosis and Pulmonary Embolism
Oct 13, 2016: Daiichi Sankyo Announces New Data to be Presented at the ISPOR EU Congress 2016 Analysing the Safety, Efficacy and Cost-effectiveness of LIXIANA (edoxaban)
Sep 01, 2016: Lixiana applies to National Health Insurance
Aug 26, 2015: UK’s NICE recommends once-daily LIXIANA (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults
Aug 07, 2015: NICE Recommends Once-daily Lixiana (Edoxaban) for Preventing Stroke and Systemic Embolism in People with Non-valvular Atrial Fibrillation
Jun 25, 2015: Daiichi Sankyo’s Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE
Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation
Dec 09, 2013: Phase 3 Data Show Daiichi Sankyo's Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer
Sep 01, 2013: Daiichi Sankyo's Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Oct 25, 2012: Daiichi Sankyo Completes Enrolment In Hokusai-VTE Phase III Study Of Edoxaban For Treatment And Prevention Of Recurrence Of VTE
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Pulmonary Embolism - Overview
Pulmonary Embolism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pulmonary Embolism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pulmonary Embolism - Companies Involved in Therapeutics Development
Acticor Biotech SAS
China Resources Emde Biological Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
Indiana Lysis Technologies LLC
Les Laboratoires Servier SAS
Tasly Pharmaceutical Group Co Ltd
Tianjin Pharmaceuticals Group Co Ltd
Valeo Pharma Inc
Verseon Corp
Pulmonary Embolism - Drug Profiles
ACT-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Pulmonary Embolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Redesca - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pulmonary Embolism - Dormant Projects
Pulmonary Embolism - Discontinued Products
Pulmonary Embolism - Product Development Milestones
Featured News & Press Releases
Nov 14, 2019: Valeo Pharma announces filing of a New Drug Submission for Low Molecular Weight Heparin in Canada
Oct 25, 2017: IU-based drug-discovery startup aims to use nanotechnology to digest blood clots in lungs
Oct 11, 2017: IU-based drug-discovery startup wins $10,000 in BioCrossroads New Venture Competition
Feb 23, 2017: Daiichi Sankyo Europe Receives CHMP Positive Opinion for Roteas (edoxaban)
Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
Nov 09, 2016: Once-Daily Anticoagulant LIXIANA (edoxaban) Approved in Canada for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrent Deep-Vein Thrombosis and Pulmonary Embolism
Oct 13, 2016: Daiichi Sankyo Announces New Data to be Presented at the ISPOR EU Congress 2016 Analysing the Safety, Efficacy and Cost-effectiveness of LIXIANA (edoxaban)
Sep 01, 2016: Lixiana applies to National Health Insurance
Aug 26, 2015: UK’s NICE recommends once-daily LIXIANA (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults
Aug 07, 2015: NICE Recommends Once-daily Lixiana (Edoxaban) for Preventing Stroke and Systemic Embolism in People with Non-valvular Atrial Fibrillation
Jun 25, 2015: Daiichi Sankyo’s Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE
Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation
Dec 09, 2013: Phase 3 Data Show Daiichi Sankyo's Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer
Sep 01, 2013: Daiichi Sankyo's Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Oct 25, 2012: Daiichi Sankyo Completes Enrolment In Hokusai-VTE Phase III Study Of Edoxaban For Treatment And Prevention Of Recurrence Of VTE
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Pulmonary Embolism, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pulmonary Embolism - Pipeline by Acticor Biotech SAS, H2 2020
Pulmonary Embolism - Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, H2 2020
Pulmonary Embolism - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
Pulmonary Embolism - Pipeline by Indiana Lysis Technologies LLC, H2 2020
Pulmonary Embolism - Pipeline by Les Laboratoires Servier SAS, H2 2020
Pulmonary Embolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2020
Pulmonary Embolism - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, H2 2020
Pulmonary Embolism - Pipeline by Valeo Pharma Inc, H2 2020
Pulmonary Embolism - Pipeline by Verseon Corp, H2 2020
Pulmonary Embolism - Dormant Projects, H2 2020
Pulmonary Embolism - Discontinued Products, H2 2020
Number of Products under Development for Pulmonary Embolism, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pulmonary Embolism - Pipeline by Acticor Biotech SAS, H2 2020
Pulmonary Embolism - Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, H2 2020
Pulmonary Embolism - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
Pulmonary Embolism - Pipeline by Indiana Lysis Technologies LLC, H2 2020
Pulmonary Embolism - Pipeline by Les Laboratoires Servier SAS, H2 2020
Pulmonary Embolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2020
Pulmonary Embolism - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, H2 2020
Pulmonary Embolism - Pipeline by Valeo Pharma Inc, H2 2020
Pulmonary Embolism - Pipeline by Verseon Corp, H2 2020
Pulmonary Embolism - Dormant Projects, H2 2020
Pulmonary Embolism - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Pulmonary Embolism, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Acticor Biotech SAS
China Resources Emde Biological Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
Indiana Lysis Technologies LLC
Les Laboratoires Servier SAS
Tasly Pharmaceutical Group Co Ltd
Tianjin Pharmaceuticals Group Co Ltd
Valeo Pharma Inc
Verseon Corp
Number of Products under Development for Pulmonary Embolism, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Acticor Biotech SAS
China Resources Emde Biological Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
Indiana Lysis Technologies LLC
Les Laboratoires Servier SAS
Tasly Pharmaceutical Group Co Ltd
Tianjin Pharmaceuticals Group Co Ltd
Valeo Pharma Inc
Verseon Corp
